SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
June 30, 2023 09:25 ET
|
SciSparc Ltd
The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to use SCI-110 in a clinical trial at the Hannover Medical School TEL AVIV, Israel, June 30, 2023 ...
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
June 21, 2023 09:00 ET
|
SciSparc Ltd
Company reaches another clinical trial milestone for treatment of Tourette’s with its novel SCI-110 therapy in the United States TEL AVIV, Israel, June 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....